Trial Profile

A pivotal phase III trial assessing UM171 in patients with high-risk leukemia and myelodysplastic-syndromes

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 05 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dorocubicel (Primary)
Indications Leukaemia; Myelodysplastic syndromes
Focus Registrational; Therapeutic Use

Most Recent Events

25 Jun 2024 According to a ExCellThera Inc. media release, The initiation of a Phase 3 trial in high and very high-risk leukemias and myelodysplasias patient population is planned for the second half of 2024.
12 Dec 2023 According to a ExCellThera Inc. media release, Phase 3 trial in high and very high-risk leukemias and myelodysplasias expected to start in 2024.
29 Mar 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com